leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 14:20:05 - browse：59567

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Biotech incubator Curie.Bio graduates its first startup

hotspot

WSS

Sanofi CEO defends move to abandon profit guidance, boost research

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Do more moles mean more problems? Not so, says new study

Startling documents reveal new facets of Sacklers' opioid empire

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Do more moles mean more problems? Not so, says new study

hotspot

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

FDA approves potent Eli Lilly obesity drug, Zepbound

Continuity nursing helped my family in our darkest PICU moments

iTeos Therapeutics debuts first data on TIGIT

Drug repurposing or repositioning? The language matters

iTeos Therapeutics debuts first data on TIGIT

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate panel clears PBM, hopsital reforms

Tori Bowie and the unacceptable rates of Black maternal death

Abortion clinic in Cancun will cater to Americans

leisure time

iTeos Therapeutics debuts first data on TIGIT

iTeos Therapeutics debuts first data on TIGIT

Lab trade group sues FDA to halt regulation of lab

MoonLake credibility takes another hit with mid

David Sabatini, ex

FDA approves Recor Medical high blood pressure device

hotspot

leisure time

entertainment

leisure time